profit from every $100 of sales.
$0$100
Cellebrite DI
$11.53+5.88% today
-40.2% in 1 year
1-year low $10.441-year high $19.28
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $37.00 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Cellebrite DI sold, what it kept, and what it did with the cash.
Sales went from $271 million in 2022 to $476 million in 2025, with $78.3 million of profit last year.
SalesProfit
Cellebrite DI vs. similar companies
Cellebrite DI grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cellebrite DI | 37.0× · Expensive | ||
 Microsoft | 29.1× · Fair price | ||
 Palantir Technologies | 249.1× · Very expensive | ||
 Oracle | 22.9× · Fair price | ||
 Palo Alto Networks | 232.7× · Very expensive |
AI analysis
An AI analyst reads Cellebrite DI's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 271 | 325 | 401 | 476 | |
| 220 | 272 | 339 | 401 | |
| 1 | 33 | 57 | 66 | |
| 130 | -65 | -265 | 103 | |
| 121 | -81 | -283 | 78 | |
| 0.59 | -0.43 | -1.35 | 0.31 | |
| 81.3% | 83.6% | 84.4% | 84.2% | |
| 0.4% | 10.2% | 14.2% | 14.0% | |
| 44.6% | -24.9% | -70.5% | 16.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 403 | 533 | 691 | 939 |
| Cash | 88 | 190 | 192 | 124 |
| Total debt | 15 | 14 | 11 | 23 |
| Total liabilities | 329 | 499 | 355 | 455 |
| 74 | 34 | 336 | 484 | |
| 195 | 190 | 209 | 250 | |
| 107.1% | -123.3% | -62.8% | 14.2% | |
| 163.5% | -237.1% | -84.2% | 16.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 21 | 102 | 132 | 174 | |
| 9 | 8 | 11 | 13 | |
| 11 | 94 | 122 | 160 | |
| Dividends paid | 0 | 0 | – | – |
| 0 | – | – | – | |
| 14 | 19 | 31 | 45 |
Valuation
- 37.0×
- 31.3×
- –
- 7.2×
- 6.1×
- 18.1×
- 27.1×
- 5.5%
- 2.7%
- 0.0%
Profitability
- 84.2%
- 14.0%
- 16.5%
- 17.6%
- 10.0%
- -39.2%
- 18.4%
- 8.3%
- 11.7%
- 23.9%
Growth
- +20.7%
- −19.3%
- +28.1%
- –
- +15.1%
Financial health
- -1.2×
- 0.05
- 2.4%
- –
- 1.56
- 1.54
- 0.51
How it ranks in Technology
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 39%of 964
Top 35%of 972
Bottom 38%of 730
Top 25%of 977
Top 26%of 981
What analysts expect
- Average price target
- $20.67
- Range
- $18.00 – $23.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | 0.04 | 0.11 | −59.6% |
| Feb 11, 2026 | 0.09 | 0.14 | −35.7% |
| Nov 12, 2025 | 0.14 | 0.09 | +48.2% |
| Aug 14, 2025 | 0.12 | 0.10 | +20.0% |
| May 14, 2025 | 0.10 | 0.05 | +90.3% |
| Feb 13, 2025 | 0.10 | 0.10 | +0.0% |
| Nov 6, 2024 | 0.14 | 0.11 | +27.3% |
| Aug 15, 2024 | 0.10 | 0.08 | +25.0% |
News
Cellebrite projects $163M-$166M adjusted EBITDA in 2026 as it reaffirms $550M-$560M ARRSeeking Alpha · Nov 12, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
27No pass
Philip Fisher
50No pass
Peter Lynch
49No pass
Joel Greenblatt
10No pass
Charlie Munger
45No pass
Terry Smith
50No pass
Questions about Cellebrite DI
Is Cellebrite DI a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cellebrite DI AI analysis
What does Cellebrite DI do?
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. It is in Software - Infrastructure, based in Petah Tikva, Israel, with 1,285 employees.
Does Cellebrite DI pay a dividend?
No. Cellebrite DI does not pay a dividend at the moment.
Is Cellebrite DI stock halal?
Yes. Cellebrite DI passes our halal screen: its business is permitted and its debt is 0.8% of its market value, under the 30% limit. How we check
How has Cellebrite DI stock done over the past year?
Down 40.2% over the past twelve months, to $11.53. It traded between $10.44 and $19.28 and is 40.2% below its high.
Who are Cellebrite DI's competitors?
The largest listed companies in the same industry are Microsoft, Palantir Technologies, Oracle and Palo Alto Networks. The peers table on this page compares their profit, growth and price with Cellebrite DI's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.